Literature DB >> 31481499

Integrated Pan-Cancer Map of EBV-Associated Neoplasms Reveals Functional Host-Virus Interactions.

Srishti Chakravorty1, Bingyu Yan1, Chong Wang2, Luopin Wang3, Joseph Taylor Quaid1, Chin Fang Lin4, Scott D Briggs1, Joydeb Majumder5, D Alejandro Canaria6, Daniel Chauss7, Gaurav Chopra5, Matthew R Olson6, Bo Zhao2, Behdad Afzali7, Majid Kazemian8,3.   

Abstract

Epstein-Barr virus (EBV) is a complex oncogenic symbiont. The molecular mechanisms governing EBV carcinogenesis remain elusive and the functional interactions between virus and host cells are incompletely defined. Here we present a comprehensive map of the host cell-pathogen interactome in EBV-associated cancers. We systematically analyzed RNA sequencing from >1,000 patients with 15 different cancer types, comparing virus and host factors of EBV+ to EBV- tissues. EBV preferentially integrated at highly accessible regions of the cancer genome, with significant enrichment in super-enhancer architecture. Twelve EBV transcripts, including LMP1 and LMP2, correlated inversely with EBV reactivation signature. Overexpression of these genes significantly suppressed viral reactivation, consistent with a "virostatic" function. In cancer samples, hundreds of novel frequent missense and nonsense variations in virostatic genes were identified, and variant genes failed to regulate their viral and cellular targets in cancer. For example, one-third of patients with EBV+ NK/T-cell lymphoma carried two novel nonsense variants (Q322X, G342X) of LMP1 and both variant proteins failed to restrict viral reactivation, confirming loss of virostatic function. Host cell transcriptional changes in response to EBV infection classified tumors into two molecular subtypes based on patterns of IFN signature genes and immune checkpoint markers, such as PD-L1 and IDO1. Overall, these findings uncover novel points of interaction between a common oncovirus and the human genome and identify novel regulatory nodes and druggable targets for individualized EBV and cancer-specific therapies. SIGNIFICANCE: This study provides a comprehensive map of the host cell-pathogen interactome in EBV+ malignancies.See related commentary by Mbulaiteye and Prokunina-Olsson, p. 5917. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31481499      PMCID: PMC6891172          DOI: 10.1158/0008-5472.CAN-19-0615

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.

Authors:  Markus P Rechsteiner; Christoph Berger; Matthias Weber; Jürg A Sigrist; David Nadal; Michele Bernasconi
Journal:  J Gen Virol       Date:  2007-05       Impact factor: 3.891

2.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.

Authors:  Steven A Roberts; Michael S Lawrence; Leszek J Klimczak; Sara A Grimm; David Fargo; Petar Stojanov; Adam Kiezun; Gregory V Kryukov; Scott L Carter; Gordon Saksena; Shawn Harris; Ruchir R Shah; Michael A Resnick; Gad Getz; Dmitry A Gordenin
Journal:  Nat Genet       Date:  2013-07-14       Impact factor: 38.330

3.  Epstein-Barr virus oncoprotein super-enhancers control B cell growth.

Authors:  Hufeng Zhou; Stefanie C S Schmidt; Sizun Jiang; Bradford Willox; Katharina Bernhardt; Jun Liang; Eric C Johannsen; Peter Kharchenko; Benjamin E Gewurz; Elliott Kieff; Bo Zhao
Journal:  Cell Host Microbe       Date:  2015-01-29       Impact factor: 21.023

4.  Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.

Authors:  Stuart Prince; Sinead Keating; Ceri Fielding; Paul Brennan; Eike Floettmann; Martin Rowe
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.

Authors:  Hae Yong Yoo; Min Kyung Sung; Seung Ho Lee; Sangok Kim; Haeseung Lee; Seongjin Park; Sang Cheol Kim; Byungwook Lee; Kyoohyoung Rho; Jong-Eun Lee; Kwang-Hwi Cho; Wankyu Kim; Hyunjung Ju; Jaesang Kim; Seok Jin Kim; Won Seog Kim; Sanghyuk Lee; Young Hyeh Ko
Journal:  Nat Genet       Date:  2014-03-02       Impact factor: 38.330

6.  Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.

Authors:  Martina Vockerodt; Wenbin Wei; Eszter Nagy; Zuzana Prouzova; Alexandra Schrader; Dieter Kube; Martin Rowe; Ciaran B Woodman; Paul G Murray
Journal:  J Pathol       Date:  2013-08       Impact factor: 7.996

7.  Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.

Authors:  Chih-Hung Hsu; Manfred Hergenhahn; Shuan-En Chuang; Pei-Yen Yeh; Ta-Chung Wu; Ming Gao; Ann-Lii Cheng
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

8.  Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

Authors:  Adam M Petrich; Violetta Leshchenko; Pei-Yu Kuo; Bing Xia; Venu K Thirukonda; Netha Ulahannan; Shanisha Gordon; Melissa J Fazzari; B Hilda Ye; Joseph A Sparano; Samir Parekh
Journal:  Clin Cancer Res       Date:  2012-02-14       Impact factor: 12.531

9.  Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics.

Authors:  Linn Fagerberg; Björn M Hallström; Per Oksvold; Caroline Kampf; Dijana Djureinovic; Jacob Odeberg; Masato Habuka; Simin Tahmasebpoor; Angelika Danielsson; Karolina Edlund; Anna Asplund; Evelina Sjöstedt; Emma Lundberg; Cristina Al-Khalili Szigyarto; Marie Skogs; Jenny Ottosson Takanen; Holger Berling; Hanna Tegel; Jan Mulder; Peter Nilsson; Jochen M Schwenk; Cecilia Lindskog; Frida Danielsson; Adil Mardinoglu; Asa Sivertsson; Kalle von Feilitzen; Mattias Forsberg; Martin Zwahlen; IngMarie Olsson; Sanjay Navani; Mikael Huss; Jens Nielsen; Fredrik Ponten; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2013-12-05       Impact factor: 5.911

10.  ViralFusionSeq: accurately discover viral integration events and reconstruct fusion transcripts at single-base resolution.

Authors:  Jing-Woei Li; Raymond Wan; Chi-Shing Yu; Ngai Na Co; Nathalie Wong; Ting-Fung Chan
Journal:  Bioinformatics       Date:  2013-01-12       Impact factor: 6.937

View more
  20 in total

Review 1.  Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses.

Authors:  Noemi Linden; R Brad Jones
Journal:  Trends Immunol       Date:  2022-07-08       Impact factor: 19.709

2.  Accurate Quantification of Overlapping Herpesvirus Transcripts from RNA Sequencing Data.

Authors:  Alejandro Casco; Akansha Gupta; Mitchell Hayes; Reza Djavadian; Makoto Ohashi; Eric Johannsen
Journal:  J Virol       Date:  2021-10-27       Impact factor: 6.549

3.  Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells.

Authors:  Luopin Wang; Jun Laing; Bingyu Yan; Hufeng Zhou; Liangru Ke; Chong Wang; Yohei Narita; Zonghao Zhang; Matthew R Olson; Behdad Afzali; Bo Zhao; Majid Kazemian
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

4.  Host-Virus Chimeric Events in SARS-CoV-2-Infected Cells Are Infrequent and Artifactual.

Authors:  Bingyu Yan; Srishti Chakravorty; Carmen Mirabelli; Christiane E Wobus; Behdad Afzali; Majid Kazemian; Luopin Wang; Jorge L Trujillo-Ochoa; Daniel Chauss; Dhaneshwar Kumar; Michail S Lionakis; Matthew R Olson
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

Review 5.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 6.  Oncogenic seRNA functional activation: a novel mechanism of tumorigenesis.

Authors:  Yuan Tan; Yuejin Li; Faqing Tang
Journal:  Mol Cancer       Date:  2020-04-11       Impact factor: 27.401

7.  Structural basis for the constitutive activity and immunomodulatory properties of the Epstein-Barr virus-encoded G protein-coupled receptor BILF1.

Authors:  Naotaka Tsutsumi; Qianhui Qu; Maša Mavri; Maibritt S Baggesen; Shoji Maeda; Deepa Waghray; Christian Berg; Brian K Kobilka; Mette M Rosenkilde; Georgios Skiniotis; K Christopher Garcia
Journal:  Immunity       Date:  2021-07-02       Impact factor: 43.474

8.  High Levels of Class I Major Histocompatibility Complex mRNA Are Present in Epstein-Barr Virus-Associated Gastric Adenocarcinomas.

Authors:  Farhad Ghasemi; Steven F Gameiro; Tanner M Tessier; Allison H Maciver; Joe S Mymryk
Journal:  Cells       Date:  2020-02-21       Impact factor: 6.600

9.  Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas.

Authors:  Enrico Tiacci; Stefano Lazzi; Lucia Mundo; Leonardo Del Porro; Massimo Granai; Maria Chiara Siciliano; Virginia Mancini; Raffaella Santi; Lynnette Marcar; Katerina Vrzalikova; Federica Vergoni; Gioia Di Stefano; Gianluca Schiavoni; Giovanna Segreto; Noel Onyango; Joshua Akelo Nyagol; Teresa Amato; Cristiana Bellan; Ioannis Anagnostopoulos; Brunangelo Falini; Lorenzo Leoncini
Journal:  Mod Pathol       Date:  2020-06-01       Impact factor: 7.842

10.  Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and artifactual.

Authors:  Bingyu Yan; Srishti Chakravorty; Carmen Mirabelli; Luopin Wang; Jorge L Trujillo-Ochoa; Daniel Chauss; Dhaneshwar Kumar; Michail S Lionakis; Matthew R Olson; Christiane E Wobus; Behdad Afzali; Majid Kazemian
Journal:  bioRxiv       Date:  2021-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.